FLUDEOXYGLUCOSE (18F)
Sponsors
Centre Hospitalier Universitaire De Nantes, Pentixapharm AG, Merck Sharp & Dohme LLC, Institut Jules Bordet, Odense University Hospital
Conditions
B-cell non-Hodgkin lymphoma (NHL)Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphomaHuntington's diseaseMarginal Zone LymphomaMarginal zone lymphoma; Follicular lymphoma; Waldenström’s macroglobulinemiaMetastatic breast cancerMultiple MyelomaPulmonary Nodule
Phase 1
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
CompletedNCT00906503
Start: 2009-04-30End: 2012-04-30Updated: 2015-04-07
An Open-Label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Active, not recruitingCTIS2023-506986-74-00
Start: 2021-12-27Target: 17Updated: 2025-08-04
(ASK-HD-01-CS-101) An Open-Label Phase I/II Dose Finding Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of AB-1001 in Adult Subjects with Early Manifest Huntington’s Disease (HD)
Active, not recruitingCTIS2024-510895-18-00
Start: 2024-11-07Target: 18Updated: 2025-11-24
Phase 2
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
CompletedCTIS2022-500339-35-01
End: 2023-05-23Target: 45Updated: 2023-03-13
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
RecruitingCTIS2023-504931-42-00
Start: 2021-04-06Target: 238Updated: 2026-01-26
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)
CompletedCTIS2023-506550-20-00
Start: 2024-07-05End: 2025-10-30Target: 30Updated: 2025-06-13
Phase 3
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients treated with definitive chemo-radiotherapy
Active, not recruitingCTIS2023-506258-19-00
Start: 2019-12-11Target: 121Updated: 2025-10-06
A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).
CompletedCTIS2022-500918-25-00
Start: 2024-05-20End: 2025-06-06Target: 148Updated: 2025-07-01
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: a multicenter randomized clinical trial (MONITOR-RCT)
RecruitingCTIS2023-508591-11-00
Start: 2025-02-25Target: 420Updated: 2025-10-01
Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors: a basket diagnostic performance study
Not yet recruitingCTIS2024-519505-35-00
Target: 28Updated: 2025-08-06